Protara Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
TARA-002 shows strong efficacy and safety in NMIBC, with six-month CR rates leading the field and a robust regulatory path for both BCG-unresponsive and BCG-naive populations. The pipeline includes a pivotal trial for lymphatic malformations and IV choline chloride, with multiple catalysts expected in 2024.
-
TARA-002 is advancing in late-stage trials for NMIBC and LM, with strong interim efficacy and safety data, and regulatory progress supporting broader market entry. IV Choline Chloride targets a large unmet need in parenteral nutrition, backed by patent protection through 2041.
-
Interim phase II results for TARA-002 in NMIBC show strong six- and twelve-month response rates in both BCG-unresponsive and BCG-naïve cohorts, with high reinduction success and a favorable safety profile. The therapy's ease of use and robust efficacy position it as a promising new option.
-
Late-stage programs in bladder cancer and lymphatic malformations are advancing, with pivotal data and regulatory clarity expected by 2026. The company targets significant rare disease markets and anticipates annual FDA approvals from 2027 to 2030, supported by strong clinical efficacy and expedited pathways.
Fiscal Year 2025
-
Updated phase II data show TARA-002 achieved a 69% six-month and 50% 12-month CR rate in BCG-naive NMIBC, with strong durability and a favorable safety profile. FDA has agreed to a registrational trial using intravesical chemotherapy as comparator, targeting fewer than 500 patients.
-
Interim phase II results for TARA-002 in pediatric lymphatic malformations show high clinical success and a favorable safety profile, consistent with historical data from OK-432. The company plans to complete the study next year and engage the FDA for potential approval, targeting a significant unmet need in this rare disease.
-
Robust clinical data in lymphatic malformations and NMIBC support regulatory filings, with interim results expected soon. TARA-002 differentiates itself from BCG with a unique mechanism, easy administration, and strong safety. Cash reserves are sufficient through 2027.
-
Key programs in oncology and rare diseases are advancing, with TARA-002 showing strong response rates in NMIBC and a major data update expected at GU ASCO. Enrollment is a top priority, with European sites driving rare disease trial progress and regulatory discussions ongoing for BCG-naive studies.
-
TARA-002, an immune-stimulating therapy for NMIBC, shows promising efficacy and durability in both BCG-unresponsive and BCG-naive settings, with a strong safety profile and ease of administration. Full enrollment is targeted by spring 2026, with key data readouts expected by year-end.
-
TARA-002, a repurposed immunopotentiator, is in late-stage development for NMIBC and rare diseases, showing strong safety and efficacy data. Recent results include a 67% 12-month CR rate in BCG-unresponsive patients, with strategies focused on regulatory flexibility and community adoption.
-
Interim phase II results for TARA-002 in NMIBC show strong safety and efficacy, with high complete response rates in both BCG unresponsive and naïve cohorts. Enrollment is accelerating, and regulatory engagement is ongoing for future studies. Durable responses and favorable tolerability position TARA-002 as a competitive therapy.
-
TARA-002 shows strong efficacy and safety in NMIBC, with high response rates in both BCG naive and unresponsive patients. Enrollment is expanding, with key data readouts expected mid- and late-2024, and future plans include broader NMIBC populations and less invasive administration.
-
Key programs include TARA-002 for NMIBC, showing strong six-month CR rates and ease of use, and a pediatric LM study with promising early responses. The IV choline chloride program targets parenteral support patients, with pivotal studies underway and robust IP protection.
-
Three late-stage programs target NMIBC, parenteral support, and lymphatic malformations, each with strong clinical data and regulatory momentum. TARA-002 shows high response rates and practical advantages in NMIBC, while IV choline and TARA-002 for LMs address significant unmet needs.
Fiscal Year 2024
-
Interim phase II results for TARA-002 in NMIBC show a 72% six-month complete response rate overall, with 100% in BCG unresponsive patients and 64% in BCG naive. The therapy demonstrated strong durability, an 80% reinduction salvage rate, and a favorable safety profile.
-
TARA-002, a broad-spectrum immunopotentiator, is advancing in NMIBC with promising early results and a registrational phase II trial. IV Choline targets a large unmet need in parenteral support patients, with pivotal data expected in 2025. TARA-002 also shows strong potential in pediatric lymphatic malformations.
-
The conference highlighted a differentiated approach leveraging de-risked assets, with TARA-002 showing promising early results in NMIBC and unique systemic dosing potential. IV Choline addresses a large unmet need in parenteral support, and strong financials support multiple upcoming catalysts.